Answers are grounded in this paper and cite their sources.
Objective Pembrolizumab plus axitinib (P + A) and pembrolizumab plus lenvatinib (P + L) are already used as first-line standard treatments for advanced renal cell carcinoma (aRCC); however, their real-world safety and the toxicity patterns that each regimen tends to cause have not been clearly and systematically explained. This study aimed to compare the adverse event (AE) spectra of these two immune checkpoint inhibitor-tyrosine kinase inhibitor (ICI-TKI) combinations; the main focus was on toxicity features specific to each regimen, differences in immune-related adverse events (irAEs), and time-to-onset patterns. Methods This study collected individual case safety reports of aRCC patients who received P + A or P + L from two independent pharmacovigilance cohorts; it used three methods for imbalance analysis, namely the reporting odds ratio (ROR), the proportional reporting ratio (PRR), and the Bayesian confidence propagation neural network (BCPNN); the rules for finding signals were set as follows: the lower limit of the 95% confidence interval (CI) of ROR > 1, PRR ≥ 2 with χ² ≥ 4, and IC₀₂₅ > 0; the analysis looked at both the System Organ Class (SOC) level and the Preferred Term (PT) level, with special attention to ten clinically relevant irAEs; these were also divided by sex, age group, and time of onset. Results A total of 897 and 648 reports were included in the P + A and P + L groups, respectively; both regimens covered a wide range of SOCs, but their safety profiles showed clear differences; P + A had more obvious signals in hepatobiliary disorders and certain immune-related toxicities, especially stronger signals for Immune-mediated hepatic disorder and Immune-mediated myocarditis; in contrast, P + L was mainly linked to vascular, renal, metabolic, and endocrine toxicities, with higher signals for Hypertension, Proteinuria, Palmar-plantar erythrodysaesthesia syndrome, and Immune-mediated hypothyroidism; subgroup analyses showed that some immune toxicities changed with age, for example, P + A-related Immune-mediated hepatic disorder had stronger signals in younger patients, while the P + L-related Hypothyroidism signals was more obvious in older patients; analysis of temporal onset showed different paths for different irAEs, such as very early start, middle-stage peak, and late build-up patterns. Several potential novel signals, including Tumor necrosis and Immune-mediated hyperthyroidism, were identified. Conclusion Pembrolizumab plus axitinib and pembrolizumab plus lenvatinib exhibited markedly distinct safety profiles in the treatment of aRCC. The P + A regimen was primarily characterized by hepatobiliary and cardiac-specific immunotoxicities, whereas the P + L regimen was more closely associated with vascular, renal, metabolic, and endocrine toxicities. Age stratification and temporal profiling provided novel evidence to inform personalized monitoring strategies. Because spontaneous reporting databases have intrinsic constraints, our observations should be confirmed in prospective clinical investigations.
No takes yet. Share an insight, caveat, or question.
Guo et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: